Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zanoz is a brand of nicotine replacement therapy (NRT) products developed by Zanoprima Life Sciences, featuring high-purity synthetic nicotine (SyNic). The product line includes nicotine pouches, chewing gum, and lozenges designed to treat nicotine dependence and facilitate smoking cessation. Unlike traditional NRTs that often use tobacco-derived nicotine, Zanoz utilizes a patented synthetic process to ensure the absence of tobacco-specific nitrosamines (TSNAs) and other impurities. The Zanoz range has entered the U.S. FDA regulatory approval process for classification as medicinal NRT products.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zanoz.